Bausch Health Companies Inc

BHC

Equity

ISIN CA0717341071 / Valor 42260834

New York Stock Exchange, Inc (2024-11-20)

USD 8.19%

Bausch Health Companies Inc
UMushroom community rating:

5.00 1 votes No rating yet

NegativeNeutralPositive

About company

Bausch Health Companies Inc. is a global pharmaceutical company focused on developing, manufacturing, and marketing a range of products primarily in gastroenterology, neurology, dermatology, and international pharmaceuticals. With a presence in over 90 countries and regions, including the United States, Canada, Europe, the Middle East, Africa, Asia Pacific, and Latin America, the company offers a broad range of branded and generic pharmaceuticals, as well as over-the-counter products. Bausch Health is committed to improving people's lives through its pharmaceutical products and is dedicated to advancing global health by delivering on its commitments to patients, healthcare providers, and other stakeholders.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue Growth

Bausch Health Companies Inc. reported first quarter 2024 revenues of $2.15 billion, marking an 11% increase on a reported basis and an 8% increase on an organic basis. This growth reflects the company's strong performance across all business segments.

Net Loss

Despite the revenue growth, Bausch Health Companies Inc. recorded a GAAP net loss attributable to the company of $64 million for the first quarter of 2024. This indicates ongoing financial challenges that the company is working to address.

Adjusted EBITDA

Bausch Health Companies Inc. achieved an adjusted EBITDA attributable to the company (non-GAAP) of $665 million in the first quarter of 2024, representing a 13% increase. This improvement highlights the company's operational efficiency and profitability.

Full-Year Guidance

Bausch Health Companies Inc. reaffirmed its full-year revenue and adjusted EBITDA (non-GAAP) guidance for 2024. This indicates the company's confidence in its financial outlook and strategic initiatives for the remainder of the year.

Xifaxan® Appeal Decision

The U.S. Court of Appeals for the Federal Circuit affirmed the decision of the U.S. District Court for the District of Delaware in the Norwich matter on April 11, 2024. This ruling prevents the FDA from approving Norwich’s abbreviated new drug application for Xifaxan® (rifaximin) 550 mg until October 2029, reinforcing Bausch Health Companies Inc.'s intellectual property and growth strategy for Salix.

Summarized from source with an LLMView Source

Key figures

16.3%1Y

-75.1%3Y

-77.8%5Y

Performance

49.6%1Y

75.4%3Y

67.4%5Y

Volatility